Lipoprotein Glomerulopathy, First Case Report from Canada

References

• Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13(2):148–153. doi:10.1016/s0272-6386(89)80134-9
   PubMed Web of Science ®Google Scholar
• Majeed NK, McLaughlin J, Gonzalez M. Lipoprotein glomerulopathy in a Hispanic female: a case report and literature review. Can J Kidney Heal Dis. 2019;6:2054358119859576. doi:10.1177/2054358119859576
   Google Scholar
• Tsimihodimos V, Elisaf M. Lipoprotein glomerulopathy. Curr Opin Lipidol. 2011;22(4):262–269. doi:10.1097/MOL.0b013e328345ebb0
   PubMed Web of Science ®Google Scholar
• Sica DA. Fibrate therapy and renal function. Curr Atheroscler Rep. 2009;11(5):338–342. doi:10.1007/s11883-009-0051-5
   PubMed Web of Science ®Google Scholar
• Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47(2):199–211. doi:10.1053/j.ajkd.2005.10.017
   PubMed Web of Science ®Google Scholar
• Saito T, Matsunaga A. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. Kidney Int. 2014;85(2):243–245. doi:10.1038/ki.2013.404
   PubMed Web of Science ®Google Scholar
• Li W, Wang Y, Han Z, Luo C, Zhang C, Xiong J. Apolipoprotein e mutation and double filtration plasmapheresis therapy on a new Chinese patient with lipoprotein glomerulopathy. Kidney Blood Press Res. 2014;39(4):330–339. doi:10.1159/000355810
   PubMed Web of Science ®Google Scholar
• Yang M, Weng Q, Pan X, et al. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations. Mol Genet Genomic Med. 2020;8(8). doi:10.1002/mgg3.1281
   Web of Science ®Google Scholar
• Yang Z, Wu H, Hu Z. [Discovery of a Chinese Tibetan patient with lipoprotein glomerulopathy due to APOE Osaka/Kurashiki variant]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020;37(2):166–169. Chinese. doi:10.3760/cma.j.issn.1003-9406.2020.02.017
   PubMedGoogle Scholar
• da Silveira-Neto JN, de Oliveira Ahn GJ, de Menezes Neves PDM, et al. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America. Diagn Pathol. 2021;16(1):65. doi:10.1186/s13000-021-01119-x
   PubMed Web of Science ®Google Scholar
• Kollbrunner L, Hirt-Minkowski P, Sanz J, et al. Case report: lipoprotein glomerulopathy complicated by atypical hemolytic uremic syndrome. Front Med. 2021;8. doi:10.3389/fmed.2021.679048
   Web of Science ®Google Scholar
• Marinaki S, Kalaitzakis E, Kolovou K, et al. A case of lipoprotein glomerulopathy in a Greek Caucasian male. Int Urol Nephrol. 2021;54(4):969–970. doi:10.1007/s11255-021-02930-7
   PubMed Web of Science ®Google Scholar
• Takasaki S, Maeda K, Joh K, et al. Macrophage infiltration into the glomeruli in lipoprotein glomerulopathy. Case Rep Nephrol Dial. 2015;5(3):204–212. doi:10.1159/000441715
   PubMedGoogle Scholar
• Usui R, Takahashi M, Nitta K, Koike M. Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation. CEN Case Rep. 2016;5(2):148–153. doi:10.1007/s13730-016-0214-5
   PubMedGoogle Scholar
• Kodera H, Mizutani Y, Sugiyama S, et al. A case of lipoprotein glomerulopathy with apoE Chicago and apoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial. 2017;7(2):112–120. doi:10.1159/000478902
   PubMedGoogle Scholar
• Wu H, Yang Y, Hu Z. The novel apolipoprotein E mutation ApoE Chengdu (c.518T>C, p.L173P) in a Chinese patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2018;25(8):733–740. doi:10.5551/jat.41996
   PubMed Web of Science ®Google Scholar
• Lui DTW, Lee ACH, Yap DYH, Chan GSW, Tan KCB. A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy. J Clin Lipidol. 2018;13(2):251–253. doi:10.1016/j.jacl.2018.12.004
   PubMed Web of Science ®Google Scholar
• Batal I, Fakhoury G, Groopman E, D’Agati VD, Morris H. Unusual case of lipoprotein glomerulopathy first diagnosed in a protocol kidney allograft biopsy. Kidney Int Rep. 2019;4(2):350–354. doi:10.1016/j.ekir.2018.09.020
   PubMed Web of Science ®Google Scholar
• Xie W, Xie Y, Lin Z, Xu X, Zhang Y. A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report. Diagn Pathol. 2019;14(1):41. doi:10.1186/s13000-019-0820-6
   PubMed Web of Science ®Google Scholar
• Morris CS, Bois MC, Aust CH, Thomas R, Sethi S, Maleszewski JJ. Intravascular cardiac lipoproteinosis: extrarenal manifestation of lipoprotein glomerulopathy. Cardiovasc Pathol. 2019;42:6–9. doi:10.1016/j.carpath.2019.04.006
   PubMed Web of Science ®Google Scholar
• Zhang P, Matalon R, Kaplan L, Kumar A, Gallo G. Lipoprotein glomerulopathy: first report in a Chinese male. Am J Kidney Dis. 1994;24(6):942–950. doi:10.1016/s0272-6386(12)81066-3
   PubMed Web of Science ®Google Scholar
• Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006;47(3):539–548. doi:10.1053/j.ajkd.2005.12.031
   PubMed Web of Science ®Google Scholar
• Rovin BH, Roncone D, McKinley A, Nadasdy T, Korbet SM, Schwartz MM. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med. 2007;357(24):2522–2524. doi:10.1056/NEJMc072088
   PubMed Web of Science ®Google Scholar
• Sethi S. Renal failure with intracapillary thrombi. Lipoprotein glomerulopathy. Kidney Int. 2008;73(9):1097–1098. doi:10.1038/ki.2008.13
   PubMed Web of Science ®Google Scholar
• Bomback AS, Song H, D’Agati VD, et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2010;25(10):3442–3446. doi:10.1093/ndt/gfq389
   PubMed Web of Science ®Google Scholar
• Boumendjel R, Papari M, Gonzalez M. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Arch Pathol Lab Med. 2010;134(2):279–282. doi:10.5858/134.2.279
   PubMed Web of Science ®Google Scholar
• Russi G, Furci L, Leonelli M, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced extracorporeal lipoprotein precipitation system): a case report. J Med Case Rep. 2009;3(1):9311. doi:10.1186/1752-1947-3-9311
   PubMedGoogle Scholar
• Pasquariello A, Pasquariello G, Innocenti M, et al. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J Nephrol. 2011;24(3):381–385. doi:10.5301/JN.2011.7772
   PubMed Web of Science ®Google Scholar
• Magistroni R, Bertolotti M, Furci L, et al. Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. Clin Med Insights Case Rep. 2013;6:189–196. doi:10.4137/CCRep.S12209
   PubMedGoogle Scholar
• Pêgas KL, Rohde R, Garcia CD, et al. Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child. J Bras Nefrol. 2014;36(1):93–95. doi:10.5935/0101-2800.20140015
   PubMedGoogle Scholar
• Sipovskii VG, Klemina IK, Zverkov RV, Dobronravov VA, Smirnov AV. [A case of diagnosing lipoprotein glomerulopathy in Russia]. Arkh Patol. 2016;78(6):52–57. Russian. doi:10.17116/patol201678652-57
   PubMedGoogle Scholar
• Meyrier A, Dairou F, Callard P, Mougenot B. Lipoprotein glomerulopathy: first case in a white European. Nephrol Dial Transplant. 1995;10(4):546–549. doi:10.1093/ndt/10.4.546
   PubMed Web of Science ®Google Scholar
• Mourad G, Djamali A, Turc-Baron C, Cristol JP. Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Nephrol Dial Transplant. 1998;13(5):1292–1294. doi:10.1093/ndt/13.5.1292
   PubMed Web of Science ®Google Scholar
• Hu Z, Huang S, Wu Y, et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int. 2014;85(2):416–424. doi:10.1038/ki.2013.335
   PubMed Web of Science ®Google Scholar
• Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (apo E Tokyo) with lipoprotein glomerulopathy. Nephron. 1999;83(3):214–218. doi:10.1159/000045513
   PubMed Web of Science ®Google Scholar
• Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol. 2000;14(2):149–151. doi:10.1007/s004670050032
   PubMed Web of Science ®Google Scholar
• Hamatani H, Hiromura K, Kobatake K, et al. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Clin Exp Nephrol. 2010;14(6):619–624. doi:10.1007/s10157-010-0333-9
   PubMed Web of Science ®Google Scholar
• Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract. 2010;114(4):c260–c267. doi:10.1159/000276578
   PubMedGoogle Scholar
• Cheung CY, Chan AOK, Chan GPT, Iu HYP, Shek CC, Chau KF. Long-term outcome of kidney transplantation in a patient with coexisting lipoprotein glomerulopathy and fibrillary glomerulonephritis. Clin Kidney J. 2014;7(4):396–398. doi:10.1093/ckj/sfu058
   PubMedGoogle Scholar
• Georgiadou D, Stamatakis K, Efthimiadou EK, et al. Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. J Lipid Res. 2013;54(1):164–176. doi:10.1194/jlr.M030965
   PubMed Web of Science ®Google Scholar
• Katsarou M, Stratikos E, Chroni A. Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy. J Lipid Res. 2018;59(12):2339–2348. doi:10.1194/jlr.M088732
   PubMed Web of Science ®Google Scholar
• Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int. 1999;56:S37–S41. doi:10.1046/j.1523-1755.1999.07110.x
   Web of Science ®Google Scholar
• Murano T, Matsumura R, Misawa Y, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg25[rarr]Cys) from a patient with lipoprotein glomerulopathy. Metabolism. 2002;51(2):201–205. doi:10.1053/meta.2002.29990
   PubMed Web of Science ®Google Scholar
• Amenomori M, Haneda M, Morikawa J, et al. A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron. 1994;67(1):109–113. doi:10.1159/000187897
   PubMed Web of Science ®Google Scholar
• Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis. 2003;169(2):293–299. doi:10.1016/s0021-9150(03)00194-1
   PubMed Web of Science ®Google Scholar
• Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis. 2003;41(1):244–249. doi:10.1053/ajkd.2003.50016
   PubMed Web of Science ®Google Scholar
• Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23(2):751–756. doi:10.1093/ndt/gfm675
   PubMed Web of Science ®Google Scholar
• Xin Z, Zhihong L, Shijun L, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant. 2008;24(3):864–869. doi:10.1093/ndt/gfn555
   PubMed Web of Science ®Google Scholar
• Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol. 2009;13(6):659–662. doi:10.1007/s10157-009-0207-1
   PubMed Web of Science ®Google Scholar